Shareholder tip: Viking Therapeutics explodes - | Novo share reacts:
Viking Therapeutics reports positive study data for VK2735, an obesity drug ...
deraktionaer.de/artikel/pharma-biotech/aktionaer-tipp-viking-therapeutics-explodiert-novo-aktie-reagiert-20409272.html
Story Details
| Last Updated | |
| Total Articles | 1 |
Main Topics
single unit of ownership in a corporation, mutual fund, or any other organization
individual or organization that owns part of a corporation through shares of its stock
Similar to This
Previous
Viking Therapeutics after the share price explosion: Analysts see more than 100 percent potential
deraktionaer.de/artikel/pharma-biotech/viking-therapeutics-nach-der-kursexplosion-analysten-sehen-mehr-als-100-prozent-potenzial-20409316.html
Novo Nordisk: Another setback - | Stock on a knife's edge: Novo Nordisk halts studies on ziltivekimab. The acquisition of Corvidia Therapeutics could prove ...
deraktionaer.de/artikel/pharma-biotech/novo-nordisk-naechster-rueckschlag-aktie-auf-messers-schneide-20408369.html
Shareholder Tip Halozyme: Top Results - | Stock Takes Off: Halozyme Therapeutics exceeds Q2 expectations with $2.28 earnings per share and $481 million in ...
deraktionaer.de/artikel/aktien/aktionaer-tipp-halozyme-top-resultate-aktie-startet-durch--20406372.html
Shareholder tip: Axsome unstoppable - | new record high: Axsome Therapeutics impresses with strong sales growth through Auvelity and receives FDA approval for ...
deraktionaer.de/artikel/deraktionaerplus/aktionaer-tipp-axsome-nicht-zu-bremsen-neues-rekordhoch--20400239.html
Paid articlePaywall Shareholder hot stock after doubling - | still buy now?: Nektar Therapeutics impresses with strong share price performance. Should you still buy now?
deraktionaer.de/artikel/deraktionaerplus/aktionaer-hot-stock-nach-der-verdopplung-jetzt-noch-kaufen-20399864.html
Eli Lilly isn't letting up: Billion-dollar deals every week: Eli Lilly acquires Ajax Therapeutics for up to $2.3 billion.
deraktionaer.de/artikel/pharma-biotech/eli-lilly-laesst-nicht-locker-milliarden-deals-im-wochentakt-20399777.html
Shareholder hot stock turns up again: Multi-year high according to figures: Further groundbreaking news is expected soon.
deraktionaer.de/artikel/pharma-biotech/aktionaer-hot-stock-dreht-wieder-auf-mehrjahreshoch-nach-zahlen-20397251.html
Shareholder hot stock with a 50 percent price jump - | what's going on?: Nektar Therapeutics stock rises 50% after positive data on atopic dermatitis ...
deraktionaer.de/artikel/deraktionaerplus/aktionaer-hot-stock-mit-50-prozent-kurssprung-was-ist-da-los-20395216.html
Dividend Guarantee GSK: Acquisition - | substantial premium: GSK plans to buy RAPT Therapeutics for $2.2 billion.
deraktionaer.de/artikel/pharma-biotech/dividenden-garant-gsk-uebernahme-satter-aufschlag-20393815.html
New Year's Eve Rocket: Axsome Takes Off After Double Top News: Axsome Therapeutics stock rises after positive FDA feedback on two drugs.
deraktionaer.de/artikel/pharma-biotech/silvester-rakete-axsome-hebt-nach-doppelten-top-news-ab-20392850.html
Danish weight loss drug maker outlines ambitious 2030 strategy, ramping up pressure on Novo, Lilly
cnbc.com/2025/12/11/zealand-pharma-unveils-2030-plan-as-weight-loss-competition-heats-up.html
AKTIONÄR Tip: Tempus AI causes biotech stock to explode: Tempus AI cooperates with Whitehawk Therapeutics to promote cancer drug research; shares of both ...
deraktionaer.de/artikel/pharma-biotech/aktionaer-tipp-tempus-ai-laesst-biotech-aktie-explodieren-20388551.html
Novo Nordisk buys US biotech company Akero - | Deutsches Ärzteblatt
aerzteblatt.de/news/novo-nordisk-kauft-us-biotech-firma-akero-eb00f355-99bd-4ac8-82cf-417332f535f0
Paid articlePaywall Viking Therapeutics: Panic Creates Opportunity: Viking Therapeutics' stock drops 40% despite strong Phase 2 weight-loss drug results. See here to know why I ...
seekingalpha.com/article/4815448-viking-therapeutics-stock-panic-creates-opportunity
Paid articlePaywall Viking Therapeutics: Phase 2 Oral Obesity Data Affirms Bear Case, Downgrade To Sell
seekingalpha.com/article/4815000-viking-therapeutics-phase-2-oral-obesity-data-affirms-bear-case-downgrade-to-sell
Wall Street: nervousness and oil prices rise - solar stocks crash, Verve Therapeutics explodes
deraktionaer.de/artikel/maerkte-forex-zinsen/wall-street-nervositaet-und-oelpreise-steigen-solar-aktien-crashen-verve-therapeutics-explodiert-20381898.html
Summit Therapeutics crashes - | BioNTech in collective punishment: Summit Therapeutics shares plunge 30% after Ivonescimab study data; BioNTech shares also ...
deraktionaer.de/artikel/pharma-biotech/summit-therapeutics-crasht-biontech-in-sippenhaft-20381105.html
Pfizer ends development of potential pill obesity treatment: Pfizer is ending the development of its potential once-daily pill treatment for obesity before ...
cnn.com/2025/04/14/health/pfizer-pill-obesity-treatment/
Key FactsPfizer Halts Development of Obesity Pill
Apr 15, 2025 · Reading time: ~30 sec.
Summary created with AI assistance · Source: cnn.com
Summary created with AI assistance · Source: cnn.com
- Pfizer is halting the development of its once-daily obesity pill following a potential drug-induced liver injury in a trial participant.
- The company had intended to advance the medication to late-stage testing but will continue exploring other obesity treatment options.
- Obesity treatments represent a lucrative market, with injectable drugs like Zepbound and Wegovy leading sales.
- Efforts are underway to create an easier-to-take pill, but existing medications face availability issues due to shortages and insurance complications.
Brilliant idea or flop? Is this medical stock now stealing the show from Novo Nordisk and Co?
boerse-online.de/nachrichten/aktien/geniale-idee-oder-flop-stiehlt-diese-medizin-aktie-novo-nordisk-und-co-jetzt-die-show-20374769.html
Mega opportunity with 220% upside: will this biotech share outperform Eli Lilly and Novo Nordisk in 2025?
boerse-online.de/nachrichten/aktien/mega-chance-mit-220-upside-haengt-diese-biotech-aktie-2025-eli-lilly-und-novo-nordisk-ab-20373941.html
Next